Pyxis Oncology Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
First off, thanks for the invitation. Excited to be here, and big appreciation to you and the team, and for all the folks dialing in. We have had a really exciting 2026 so far. Really impressive data that we shared just a couple months ago, a couple fundraisings that have set us off on a path to set up, stand up a pivotal trial in the middle part of 2027. We are excited about the progress we are making on this novel first-in-concept ADC that I know we will talk about.
the work that the team is doing. I am really privileged to be here representing our small but mighty Pyxis team.
All right. Obviously there is a lot going on in the head and neck space right now, and we will try to get to some or all of that. But maybe you can just kind of first give us a lay of the land with respect to MICVO, the data you have generated to date, and then maybe just kind of briefly highlight what differentiates MICVO from other ADCs with respect to design mechanism, and then how you settled on head and neck as kind of this lead tumor type.
Yeah. Well, let us start with maybe the middle part of your question around what is MICVO. It is a first-in-concept ADC. We set out to design a program that targeted the extracellular matrix, and the specific target is called EDB+FN. Important because we find EDB+FN in almost every solid tumor around, but we do not find it in normal tissue. So, the premise was let us go out and pursue this target with a novel ADC, with a payload that has been optimized for this specific place. We did a large basket study, and we were lucky enough to see strong signals for this ADC in multiple tumor types, but the strongest was head and neck cancer.
That led us to then take a look at where we thought we could have the biggest impact. Head and neck at that time, second-line head and neck specifically, there weren't a lot of things being developed in second-line head and neck, and it was a really large patient population. I hope we can get there a little bit later, but we estimate that there are 20,000 patients that are going to be seeking treatment in second-line head and neck. Those two things, we saw really nice clinical activity in head and neck cancer. We saw an opportunity where we could become the standard of care in a patient population that was large enough to matter, so we started pursuing MICVO in second-line head and neck cancer.
All right. Maybe we can jump into the dose expansion data that you provided back in September.
Yep. Before we do that, maybe just kind of remind us of the general trial design, and some of the key questions that you were trying to answer within the context of this dose expansion effort specifically.
Yeah. There were multiple questions we were trying to answer, but it started with, we had two arms in the study. One of them was platinum plus PD-1, prior treatment of platinum and PD-1, so the current standard of care in frontline head and neck cancer. We wanted to see how MICVO would perform after the current standard of care, but we also had an arm that was EGFR inhibitor plus PD-1 so that we could evaluate how MICVO performed after what we believed was going to be the future standard of care. We started enrolling patients in 2025 in that study, and we disclosed some data at the end of 2025 that showed two things. So an early look at the data, really impressive response rates, up in the 40% range, but we had a limiting toxicity that was being driven by patients that were high body weight.
In December of last year, we decided to implement what is called a dose cap or modified weight-based dosing for those patients. From that moment on, end of December, moving forward, we saw an explosive enrollment in our study. I think mainly driven by the physicians were extraordinarily excited by the efficacy data and really comfortable with a modified weight-based dose approach that is often used for ADCs. The data that we shared in September was more patients that were following the current standard of care as well as the future standard of care. We were able to look at, because of the size of the study, patients regardless of their HPV status, regardless of prior treatment, and showed all the activity for each one of those subgroups in the data.
We were also looking to see what impact the dose cap would have on safety, and we were happy to see that we nearly cut the discontinuation rate in half, and as well for any grade 3 peripheral neuropathy. We left the September data, and I am happy to get into more of the details, but really confident that we have a profile that is ready to move into a pivotal trial.
Okay. Yeah, maybe on those details, I thought the headline efficacy data read really well. It was pretty impressive. Maybe you can just kind of talk about like which of those efficacy data points really kind of stood out for you, and maybe talk about that in the context of what are some of the existing kind of second-line efficacy benchmarks that you think are the most relevant?
Well, I mean, I think it would be inappropriate for me to pick one because I think it is all of them together. Maybe for those people that are not as familiar with the data, we showed a 36% response rate regardless of HPV status. We showed a 94% disease control rate, highest that I think anyone has ever produced before, followed by a 6.2-month median PFS and a 79% OS probability. I think the four of them together really matter, but what we heard from our physicians, who were enrolling patients in the study, is one of the things that they really like about what they saw in the MICVO data was that these responses were both fast and deep.
More than two-thirds of the patients saw their response at the first scan, so that is six weeks, and more than half the patients saw greater than a 50% reduction in their tumor. This matters for a head and neck cancer patient because it is really hard to eat or drink, sometimes even speak, so to have rapid and deep responses in this patient population means a lot. For us, as we think about, is it worthy of continued investigation and getting ready for a pivotal trial? Seeing all three, response rate followed by PFS, followed by overall survival, gives us a lot of confidence that the efficacy benefit for this drug is very clear.
Okay. I know that there were some initial questions when the data was disclosed about this discrepancy in response rate that was observed as a function of prior EGFR inhibition. Again, this is a patient population that is probably of the most interest to investors, probably more so now post the Genmab disclosure. What is your level of confidence that this delta that we saw was driven more by prior treatment intensity and not some kind of biological phenomenon?
Yeah. Maybe let us just start with going back to the trial design. We enrolled patients that got the combination of EGFR inhibitor plus some PD-1s, and we had about 57% of the patients enrolled in the trial got an EGFR or received an EGFR in an earlier line. We also had about five patients that got one of the EGFR bispecifics in the data prior to getting MICVO. I think what excites us, and it started when we started designing this trial, the KOLs told us, "Look, the future is going to be EGFR bispecifics in the frontline, and it is going to be really important that you study this patient population." So we were excited about this innovative global trial that we designed. I think as far as we can tell, this is the best dataset ever produced post an EGFR in head and neck cancer.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
